Compare Huntington Ingalls Industries Inc (HII) vs Moderna, Inc. (MRNA) Price & Performance

HII trades at $265.02, up 1.67% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with a $57.3B backlog, 5.01% net margin, and attractive valuation at P/E 15.78. Recent contract wins including the $5.1B Truman RCOH and 10 ROMULUS USVs provide revenue visibility. Technical indicators show resistance at $268 with support at $261, while moving averages signal bearish pressure.

HII presents a compelling value opportunity with analyst consensus target of $363.67 (37% upside) and 40.74% buy ratings. Strong defense budget tailwinds and contract momentum offset near-term technical weakness. Risks include execution challenges on large contracts and defense spending volatility. The stock offers defensive exposure with dividend yield and consistent earnings growth.

Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.

While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.